Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emi Taniguchi
Observed name:
E. Taniguchi
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0009-0008-9209-3211
Observed ORCID:
0009-0008-9209-3211
OpenAlex ID:
A5126203160
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
2026
·
Yukinori Ozaki
, Emi Taniguchi
, et al.
·
The Breast
MO33-3 Real-world event-free survival of chemotherapy plus pembrolizumab for early-stage triple-negative breast cancer
2026
·
Y. Aoyama
, Y. Ozaki
, et al.
·
Annals of Oncology
Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
BMC Cancer
573eP Impact of HER2-low expression on the efficacy of paclitaxel plus bevacizumab in metastatic breast cancer
2026
·
E. Taniguchi
, Y. Ozaki
, et al.
·
ESMO Open
511P Time to maximal response of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer: A multicenter retrospective study (TRACE)
2026
·
Y. Ozaki
, E. Taniguchi
, et al.
·
ESMO Open
552eP Treatment patterns and clinical outcomes in metastatic triple-negative breast cancer in Japan: A high-resolution real-world study based on the integrated cancer clinical database
2026
·
M. Kuno
, T. Kobayashi
, et al.
·
ESMO Open
Abstract PS2-03-29: Evaluating Prognosis According to Axillary Surgery in Breast Cancer Patients with Isolated Internal Mammary Lymph Node Metastasis (cN2b): A Retrospective Cohort Study
2026
·
Y. Ishizaka
, T. Sakai
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
7
Citation count:
H-index:
I10-index:
Year
Topic
Type